Rani Therapeutics RANI 深 滬
等待開盤 09-25 09:30:00 美东时间
0.749
-0.018
-2.35%
華盛通- 最 高0.7856
- 今 開0.7773
- 成交量 60.50万股
- 最 低 0.749
- 昨 收 0.767
- 總市值 1.04亿
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 0.4453
- 委 比 -66.30%
- 總股本 1.39亿
- 歷史最高 36.27
- 量 比 1.00
- 振 幅 4.77%
- 歷史最低 0.387
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rani Therapeutics to Participate in Upcoming September Conferences
Rani Therapeutics announced that its management team will participate in two upcoming conferences in September 2026. The company will attend the 10th Annual BIG10 Conference hosted by Lake Street Capital Markets on September 10 in New York, featuring 1x1 meetings. Additionally, Rani's CEO Talat Imran and CFO Nicholas Maestas will engage in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14 at 4:00pm E....
09-08 12:00
美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.
08-21 18:31
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 77.78 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $1.708 mi...
08-14 04:32
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Rani Therapeutics reported positive Phase 1a data for RT-114, showing oral bioavailability exceeding 150% of matched subcutaneous dosing. The company advanced its RaniPill platform, completed a $20 million registered direct offering, and expanded its obesity pipeline through a collaboration with PegBio. Additionally, Nicholas Maestas was appointed as Chief Financial Officer, and Michelle Gilson joined the Board of Directors. The company ended the...
08-13 20:05
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
Rani Therapeutics appoints Michelle Gilson to its Board of Directors, where she will serve as Chair of the Audit Committee. Gilson, former CFO of Arcellx, brings extensive capital markets and biotech financial leadership experience. Her expertise in financial strategy and corporate governance is expected to support Rani's growth and strategic initiatives. Gilson's background includes leading Arcellx through its acquisition by Gilead and collabora...
08-04 12:00
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rani Therapeutics granted Nicholas Maestas, its new CFO, a stock option to purchase 2,000,000 shares of Class A common stock with an exercise price of $0.6973 per share. The option vests over four years, with 25% vesting after the first year and the remaining shares vesting quarterly over the next three years. The grant was approved by the Compensation Committee under the 2026 Equity Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4...
07-20 20:05
派格生物医药-B盘中大涨超22% 牵手Rani推进多项代谢创新资产口服化
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 派格生物医药-B（02565）早盘一度大涨超22%，截至发稿，股价上涨15....
07-10 09:56
